Stevanato Group S.p.A Net Cash Flow 2021-2025 | STVN

Stevanato Group S.p.A net cash flow for the twelve months ending June 30, 2025 was $0.028B, a 112.87% decline year-over-year.

  • Stevanato Group S.p.A annual net cash flow for 2024 was $0.031B, a 118.01% decline from 2023.
  • Stevanato Group S.p.A annual net cash flow for 2023 was $-0.172B, a 10.33% decline from 2022.
  • Stevanato Group S.p.A annual net cash flow for 2022 was $-0.192B, a 154.95% decline from 2021.

Stevanato Group S.p.A Net Cash Flow 2021-2025 | STVN

  • Stevanato Group S.p.A annual net cash flow for 2024 was $0.031B, a 118.01% decline from 2023.
  • Stevanato Group S.p.A annual net cash flow for 2023 was $-0.172B, a 10.33% decline from 2022.
  • Stevanato Group S.p.A annual net cash flow for 2022 was $-0.192B, a 154.95% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$70.5B
Zoetis (ZTS)$69.4B
Takeda Pharmaceutical (TAK)$49.4B
Daiichi Sankyo, - (DSNKY)$48.3B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$27.6B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$17B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14.1B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.4B
Orion OYJ (ORINY)$11.3B
Eisai (ESAIY)$9.3B
Madrigal Pharmaceuticals (MDGL)$9.2B
Corcept Therapeutics (CORT)$7.4B
Grifols, S.A (GRFS)$7B
Ionis Pharmaceuticals (IONS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.6B
Hypermarcas (HYPMY)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B
Endo (NDOI)$1.8B